These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 7588568)

  • 1. Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken.
    Magdolen V; Rettenberger P; Lopens A; Oi H; Lottspeich F; Kellermann J; Creutzburg S; Goretzki L; Weidle UH; Wilhelm O
    Electrophoresis; 1995 May; 16(5):813-6. PubMed ID: 7588568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
    Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
    Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
    Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
    Am J Pathol; 1997 Apr; 150(4):1231-44. PubMed ID: 9094980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells.
    Ploug M; Rahbek-Nielsen H; Nielsen PF; Roepstorff P; Dano K
    J Biol Chem; 1998 May; 273(22):13933-43. PubMed ID: 9593742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
    Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
    Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
    Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
    Biochem J; 2001 Sep; 358(Pt 3):673-9. PubMed ID: 11535128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
    Ellis V
    J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
    Liang OD; Chavakis T; Kanse SM; Preissner KT
    J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
    Bürgle M; Koppitz M; Riemer C; Kessler H; König B; Weidle UH; Kellermann J; Lottspeich F; Graeff H; Schmitt M; Goretzki L; Reuning U; Wilhelm O; Magdolen V
    Biol Chem; 1997; 378(3-4):231-7. PubMed ID: 9165076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
    Gårdsvoll H; Werner F; Søndergaard L; Danø K; Ploug M
    Protein Expr Purif; 2004 Apr; 34(2):284-95. PubMed ID: 15003263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex.
    Wilhelm S; Wilhelm O; Schmitt M; Graeff H
    Biol Chem Hoppe Seyler; 1994 Sep; 375(9):603-8. PubMed ID: 7840902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
    Jacobsen B; Gårdsvoll H; Juhl Funch G; Ostergaard S; Barkholt V; Ploug M
    Protein Expr Purif; 2007 Apr; 52(2):286-96. PubMed ID: 17027282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.
    Fowler B; Mackman N; Parmer RJ; Miles LA
    Thromb Haemost; 1998 Jul; 80(1):148-54. PubMed ID: 9684801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M
    Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
    Magdolen V; Krüger A; Sato S; Nagel J; Sperl S; Reuning U; Rettenberger P; Magdolen U; Schmitt M
    Recent Results Cancer Res; 2003; 162():43-63. PubMed ID: 12790320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay.
    Rønne E; Behrendt N; Ploug M; Nielsen HJ; Wöllisch E; Weidle U; Danø K; Høyer-Hansen G
    J Immunol Methods; 1994 Jan; 167(1-2):91-101. PubMed ID: 8308290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
    Wilhelm O; Weidle U; Höhl S; Rettenberger P; Schmitt M; Graeff H
    FEBS Lett; 1994 Jan; 337(2):131-4. PubMed ID: 8287966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.